{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:24:56Z","timestamp":1790645096553,"version":"4.1.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR002319"],"award-info":[{"award-number":["5UL1TR002319"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["1R01AG067788"],"award-info":[{"award-number":["1R01AG067788"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Early-onset\u00a0Alzheimer\u2019s disease (AD) is associated with variants in\u00a0amyloid precursor protein (APP) and presenilin\u00a0(PSEN)\u00a01 and\u00a02.\u00a0It is increasingly recognized that patients with AD experience undiagnosed focal seizures. These AD patients with reported seizures\u00a0may\u00a0have worsened disease trajectory. Seizures in epilepsy can also lead to cognitive deficits, neuroinflammation, and neurodegeneration. Epilepsy is roughly three times more common in individuals aged 65 and older. Due to the numerous available antiseizure drugs (ASDs), treatment of seizures has been proposed to reduce the burden of AD. More work is needed to establish the functional impact of seizures in AD to determine whether ASDs could be a rational therapeutic strategy. The efficacy of ASDs in aged animals is not routinely studied, despite the fact that the elderly represents the fastest growing demographic with epilepsy. This leaves a particular gap in understanding the discrete pathophysiological overlap between hyperexcitability and aging, and AD more specifically. Most of our preclinical knowledge of hyperexcitability in AD has come from mouse models that overexpress APP. While these studies have been invaluable, other drivers underlie AD, e.g. PSEN2. A diversity of animal models should be more frequently integrated into the study of hyperexcitability in AD, which could be particularly beneficial to identify novel therapies. Specifically, AD-associated risk genes, in particular PSENs,\u00a0altogether represent underexplored contributors\u00a0to hyperexcitability. This review assesses the available studies of ASDs administration in clinical AD populations and preclinical studies with AD-associated models and offers a perspective on the opportunities for further therapeutic innovation.<\/jats:p>","DOI":"10.1007\/s11064-021-03332-y","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T07:05:12Z","timestamp":1619766312000},"page":"1895-1912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Alzheimer\u2019s Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation"],"prefix":"10.1007","volume":"46","author":[{"given":"Leanne","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-0553","authenticated-orcid":false,"given":"Melissa","family":"Barker-Haliski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"5","key":"3332_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1528-1167.2006.00554.x","volume":"47","author":"JC Amatniek","year":"2006","unstructured":"Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer\u2019s disease. Epilepsia 47(5):867\u2013872. https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00554.x","journal-title":"Epilepsia"},{"issue":"8","key":"3332_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/archneurol.2009.130","volume":"66","author":"N Scarmeas","year":"2009","unstructured":"Scarmeas N, Honig LS, Choi H, Cantero J, Brandt J, Blacker D, Albert M, Amatniek JC, Marder K, Bell K, Hauser WA, Stern Y (2009) Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 66(8):992\u2013997. https:\/\/doi.org\/10.1001\/archneurol.2009.130","journal-title":"Arch Neurol"},{"issue":"6","key":"3332_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm.4330","volume":"23","author":"AD Lam","year":"2017","unstructured":"Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ (2017) Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer\u2019s disease. Nat Med 23(6):678\u2013680. https:\/\/doi.org\/10.1038\/nm.4330","journal-title":"Nat Med"},{"key":"3332_CR4","first-page":"921","volume":"44","author":"RF Ackermann","year":"1986","unstructured":"Ackermann RF, Engel J Jr, Phelps ME (1986) Identification of seizure-mediating brain structures with the deoxyglucose method: studies of human epilepsy with positron emission tomography, and animal seizure models with contact autoradiography. Adv Neurol 44:921\u2013934","journal-title":"Adv Neurol"},{"issue":"3","key":"3332_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1096-9861(19970901)385:3<385::AID-CNE4>3.0.CO;2-#","volume":"385","author":"PS Buckmaster","year":"1997","unstructured":"Buckmaster PS, Dudek FE (1997) Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385(3):385\u2013404","journal-title":"J Comp Neurol"},{"issue":"Pt 4","key":"3332_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/brain\/115.4.1001","volume":"115","author":"MJ Cook","year":"1992","unstructured":"Cook MJ, Fish DR, Shorvon SD, Straughan K, Stevens JM (1992) Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 115(Pt 4):1001\u20131015","journal-title":"Brain"},{"issue":"10","key":"3332_CR7","first-page":"1607","volume":"30","author":"F Fazekas","year":"1989","unstructured":"Fazekas F, Alavi A, Chawluk JB, Zimmerman RA, Hackney D, Bilaniuk L, Rosen M, Alves WM, Hurtig HI, Jamieson DG et al (1989) Comparison of CT, MR, and PET in Alzheimer\u2019s dementia and normal aging. J Nucl Med 30(10):1607\u20131615","journal-title":"J Nucl Med"},{"issue":"2","key":"3332_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3233\/JAD-2010-100846","volume":"22","author":"RG Struble","year":"2010","unstructured":"Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX (2010) Is brain amyloid production a cause or a result of dementia of the Alzheimer\u2019s type? J Alzheimers Dis 22(2):393\u2013399. https:\/\/doi.org\/10.3233\/JAD-2010-100846","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"3332_CR9","doi-asserted-by":"publisher","first-page":"a022863","DOI":"10.1101\/cshperspect.a022863","volume":"5","author":"M Barker-Haliski","year":"2015","unstructured":"Barker-Haliski M, White HS (2015) Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb Perspect Med 5(8):a022863. https:\/\/doi.org\/10.1101\/cshperspect.a022863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3332_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fnmol.2018.00217","volume":"11","author":"R Falcon-Moya","year":"2018","unstructured":"Falcon-Moya R, Sihra TS, Rodriguez-Moreno A (2018) Kainate receptors: role in epilepsy. Front Mol Neurosci 11:217. https:\/\/doi.org\/10.3389\/fnmol.2018.00217","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"3332_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/cns.12095","volume":"19","author":"Z Esposito","year":"2013","unstructured":"Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A (2013) Amyloid beta, glutamate, excitotoxicity in Alzheimer\u2019s disease: are we on the right track? CNS Neurosci Ther 19(8):549\u2013555. https:\/\/doi.org\/10.1111\/cns.12095","journal-title":"CNS Neurosci Ther"},{"issue":"33","key":"3332_CR12","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","volume":"25","author":"MT Kabir","year":"2019","unstructured":"Kabir MT, Sufian MA, Uddin MS, Begum MM, Akhter S, Islam A, Mathew B, Islam MS, Amran MS, Md Ashraf G (2019) NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer\u2019s therapy. Curr Pharm Des 25(33):3506\u20133518. https:\/\/doi.org\/10.2174\/1381612825666191011102444","journal-title":"Curr Pharm Des"},{"issue":"6","key":"3332_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s0896-6273(03)00124-7","volume":"37","author":"F Kamenetz","year":"2003","unstructured":"Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37(6):925\u2013937. https:\/\/doi.org\/10.1016\/s0896-6273(03)00124-7","journal-title":"Neuron"},{"issue":"6","key":"3332_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48(6):913\u2013922. https:\/\/doi.org\/10.1016\/j.neuron.2005.10.028","journal-title":"Neuron"},{"issue":"6453","key":"3332_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP, Sakmann B, Walsh DM, Konnerth A (2019) A vicious cycle of beta amyloid-dependent neuronal hyperactivation. Science 365(6453):559\u2013565. https:\/\/doi.org\/10.1126\/science.aay0198","journal-title":"Science"},{"issue":"22","key":"3332_CR16","doi-asserted-by":"publisher","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","volume":"287","author":"W Fu","year":"2012","unstructured":"Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH (2012) Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 287(22):18820\u201318830. https:\/\/doi.org\/10.1074\/jbc.M111.331181","journal-title":"J Biol Chem"},{"issue":"13","key":"3332_CR17","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","volume":"261","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261(13):6084\u20136089","journal-title":"J Biol Chem"},{"issue":"13","key":"3332_CR18","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83(13):4913\u20134917. https:\/\/doi.org\/10.1073\/pnas.83.13.4913","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"3332_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","volume":"16","author":"KA Vossel","year":"2017","unstructured":"Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL (2017) Epileptic activity in Alzheimer\u2019s disease: causes and clinical relevance. The Lancet Neurology 16(4):311\u2013322. https:\/\/doi.org\/10.1016\/S1474-4422(17)30044-3","journal-title":"The Lancet Neurology"},{"key":"3332_CR20","doi-asserted-by":"publisher","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","volume":"168","author":"GJ Sills","year":"2020","unstructured":"Sills GJ, Rogawski MA (2020) Mechanisms of action of currently used antiseizure drugs. Neuropharmacology 168:107966. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107966","journal-title":"Neuropharmacology"},{"issue":"3","key":"3332_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","volume":"74","author":"A Bakker","year":"2012","unstructured":"Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74(3):467\u2013474. https:\/\/doi.org\/10.1016\/j.neuron.2012.03.023","journal-title":"Neuron"},{"issue":"4","key":"3332_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.yebeh.2010.01.015","volume":"17","author":"E Cumbo","year":"2010","unstructured":"Cumbo E, Ligori LD (2010) Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer\u2019s disease. Epilepsy Behav 17(4):461\u2013466. https:\/\/doi.org\/10.1016\/j.yebeh.2010.01.015","journal-title":"Epilepsy Behav"},{"issue":"42","key":"3332_CR23","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","volume":"109","author":"PE Sanchez","year":"2012","unstructured":"Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer\u2019s disease model. Proc Natl Acad Sci USA 109(42):E2895-2903. https:\/\/doi.org\/10.1073\/pnas.1121081109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3332_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P (2018) Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 75(3):279\u2013286. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949","journal-title":"JAMA Neurol"},{"key":"3332_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1636782","author":"M Barker-Haliski","year":"2019","unstructured":"Barker-Haliski M (2019) How do we choose the appropriate animal model for antiseizure therapy development? Expert Opin Drug Discov. https:\/\/doi.org\/10.1080\/17460441.2019.1636782","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"3332_CR26","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1007\/s11064-017-2227-7","volume":"42","author":"ML Barker-Haliski","year":"2017","unstructured":"Barker-Haliski ML, Johnson K, Billingsley P, Huff J, Handy LJ, Khaleel R, Lu Z, Mau MJ, Pruess TH, Rueda C, Saunders G, Underwood TK, Vanegas F, Smith MD, West PJ, Wilcox KS (2017) Validation of a preclinical drug screening platform for pharmacoresistant epilepsy. Neurochem Res 42(7):1904\u20131918. https:\/\/doi.org\/10.1007\/s11064-017-2227-7","journal-title":"Neurochem Res"},{"key":"3332_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-017-2275-z","author":"JH Kehne","year":"2017","unstructured":"Kehne JH, Klein BD, Raeissi S, Sharma S (2017) The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-017-2275-z","journal-title":"Neurochem Res"},{"key":"3332_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107811","author":"KS Wilcox","year":"2019","unstructured":"Wilcox KS, West PJ, Metcalf CS (2019) The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107811","journal-title":"Neuropharmacology"},{"issue":"42","key":"3332_CR29","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","volume":"114","author":"JS Kaplan","year":"2017","unstructured":"Kaplan JS, Stella N, Catterall WA, Westenbroek RE (2017) Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 114(42):11229\u201311234. https:\/\/doi.org\/10.1073\/pnas.1711351114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3332_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3233\/JAD-150096","volume":"52","author":"B Cretin","year":"2016","unstructured":"Cretin B, Sellal F, Philippi N, Bousiges O, Di Bitonto L, Martin-Hunyadi C, Blanc F (2016) Epileptic prodromal Alzheimer\u2019s disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer\u2019s disease to an epileptic variant? J Alzheimers Dis 52(3):1125\u20131133. https:\/\/doi.org\/10.3233\/JAD-150096","journal-title":"J Alzheimers Dis"},{"key":"3332_CR31","unstructured":"Lam AD, Pellerin K, Gomperts S, Cole AJ, Cash SS SUBCLINICAL EPILEPTIFORM ABNORMALITIES IN PATIENTS WITH LATE-ONSET ALZHEIMER'S DISEASE. In: American Epilepsy Society Annual Meeting, Washington, D.C., December 4, 2017 2017b. p Abst. 3.084"},{"issue":"9","key":"3332_CR32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","volume":"70","author":"KA Vossel","year":"2013","unstructured":"Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70(9):1158\u20131166. https:\/\/doi.org\/10.1001\/jamaneurol.2013.136","journal-title":"JAMA Neurol"},{"key":"3332_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eplepsyres.2017.12.016","volume":"140","author":"L Hernandez-Ronquillo","year":"2018","unstructured":"Hernandez-Ronquillo L, Adams S, Ballendine S, Tellez-Zenteno JF (2018) Epilepsy in an elderly population: classification, etiology and drug resistance. Epilepsy Res 140:90\u201394. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.12.016","journal-title":"Epilepsy Res"},{"issue":"8","key":"3332_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS, Alzheimer\u2019s Disease Cooperative Study G (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 68(8):853\u2013861. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.72","journal-title":"Arch Gen Psychiatry"},{"issue":"13","key":"3332_CR35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR Jr, Weiner MW, Thomas RG, Schneider LS, Tariot PN, Alzheimer\u2019s Disease Cooperative S (2011) Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77(13):1263\u20131271. https:\/\/doi.org\/10.1212\/WNL.0b013e318230a16c","journal-title":"Neurology"},{"issue":"10","key":"3332_CR36","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1468-1331.2007.01907.x","volume":"14","author":"V Belcastro","year":"2007","unstructured":"Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L (2007) Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 14(10):1176\u20131178. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01907.x","journal-title":"Eur J Neurol"},{"issue":"5","key":"3332_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00004714-199710000-00002","volume":"17","author":"ES Barratt","year":"1997","unstructured":"Barratt ES, Stanford MS, Felthous AR, Kent TA (1997) The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 17(5):341\u2013349","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"3332_CR38","first-page":"320","volume":"28","author":"G Gobbi","year":"2003","unstructured":"Gobbi G, Debonnel G (2003) What is a recommended treatment for aggression in a patient with schizophrenia? J Psychiatry Neurosci 28(4):320","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"3332_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11940-009-0043-3","volume":"11","author":"MS Stanford","year":"2009","unstructured":"Stanford MS, Anderson NE, Lake SL, Baldridge RM (2009) Pharmacologic treatment of impulsive aggression with antiepileptic drugs. Curr Treat Options Neurol 11(5):383\u2013390","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"3332_CR40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/j.1950-6945.2000.tb00363.x","volume":"2","author":"P Genton","year":"2000","unstructured":"Genton P, Van Vleymen B (2000) Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2(2):99\u2013105","journal-title":"Epileptic Disord"},{"issue":"10216","key":"3332_CR41","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B, Group FADS (2019) Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 394(10216):2243\u20132254. https:\/\/doi.org\/10.1016\/S0140-6736(19)32500-0","journal-title":"Lancet"},{"issue":"2","key":"3332_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/epi.14629","volume":"60","author":"PH Patra","year":"2019","unstructured":"Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ (2019) Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia 60(2):303\u2013314. https:\/\/doi.org\/10.1111\/epi.14629","journal-title":"Epilepsia"},{"issue":"7","key":"3332_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archfami.3.7.589","volume":"3","author":"JC Cloyd","year":"1994","unstructured":"Cloyd JC, Lackner TE, Leppik IE (1994) Antiepileptics in the elderly Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 3(7):589\u2013598","journal-title":"Arch Fam Med"},{"issue":"7","key":"3332_CR44","doi-asserted-by":"publisher","first-page":"M384","DOI":"10.1093\/gerona\/55.7.M384","volume":"55","author":"J Garrard","year":"2000","unstructured":"Garrard J, Cloyd J, Gross C, Hardie N, Thomas L, Lackner T, Graves N, Leppik I (2000) Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A 55(7):M384-392","journal-title":"J Gerontol A"},{"issue":"10","key":"3332_CR45","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1528-1157.1998.tb01294.x","volume":"39","author":"TE Lackner","year":"1998","unstructured":"Lackner TE, Cloyd JC, Thomas LW, Leppik IE (1998) Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 39(10):1083\u20131087","journal-title":"Epilepsia"},{"issue":"3","key":"3332_CR46","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/epi.14010","volume":"59","author":"E Faught","year":"2018","unstructured":"Faught E, Szaflarski JP, Richman J, Funkhouser E, Martin RC, Piper K, Dai C, Juarez L, Pisu M (2018) Risk of pharmacokinetic interactions between antiepileptic and other drugs in older persons and factors associated with risk. Epilepsia 59(3):715\u2013723. https:\/\/doi.org\/10.1111\/epi.14010","journal-title":"Epilepsia"},{"issue":"1","key":"3332_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54(1):11\u201327. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03671.x","journal-title":"Epilepsia"},{"issue":"4","key":"3332_CR48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archneurol.2010.49","volume":"67","author":"H Arif","year":"2010","unstructured":"Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR Jr, Bazil CW, Hirsch LJ (2010) Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 67(4):408\u2013415. https:\/\/doi.org\/10.1001\/archneurol.2010.49","journal-title":"Arch Neurol"},{"issue":"1","key":"3332_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12877-019-1058-6","volume":"19","author":"ZA Marcum","year":"2019","unstructured":"Marcum ZA, Walker RL, Jones BL, Ramaprasan A, Gray SL, Dublin S, Crane PK, Larson EB (2019) Patterns of antihypertensive and statin adherence prior to dementia: findings from the adult changes in thought study. BMC Geriatr 19(1):41. https:\/\/doi.org\/10.1186\/s12877-019-1058-6","journal-title":"BMC Geriatr"},{"issue":"1","key":"3332_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1535-7511.2009.01341.x","volume":"10","author":"KM Kelly","year":"2010","unstructured":"Kelly KM (2010) Aging models of acute seizures and epilepsy. Epilepsy Curr 10(1):15\u201320. https:\/\/doi.org\/10.1111\/j.1535-7511.2009.01341.x","journal-title":"Epilepsy Curr"},{"key":"3332_CR51","doi-asserted-by":"crossref","unstructured":"Koneval Z, Knox KM, Memon A, Zierath DK, White HS, Barker-Haliski M (2020b) Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred versus inbred mice. Epilepsia (In press)","DOI":"10.1111\/epi.16624"},{"issue":"2","key":"3332_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/epi.12893","volume":"56","author":"K Leclercq","year":"2015","unstructured":"Leclercq K, Kaminski RM (2015) Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia 56(2):310\u2013318. https:\/\/doi.org\/10.1111\/epi.12893","journal-title":"Epilepsia"},{"issue":"4","key":"3332_CR53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eplepsyres.2014.02.013","volume":"108","author":"K Leclercq","year":"2014","unstructured":"Leclercq K, Matagne A, Kaminski RM (2014) Low potency and limited efficacy of antiepileptic drugs in the mouse 6 Hz corneal kindling model. Epilepsy Res 108(4):675\u2013683. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.02.013","journal-title":"Epilepsy Res"},{"issue":"3","key":"3332_CR54","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1006\/geno.2001.6564","volume":"74","author":"WN Frankel","year":"2001","unstructured":"Frankel WN, Taylor L, Beyer B, Tempel BL, White HS (2001) Electroconvulsive thresholds of inbred mouse strains. Genomics 74(3):306\u2013312","journal-title":"Genomics"},{"issue":"1","key":"3332_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1528-1157.1986.tb03496.x","volume":"27","author":"FL Engstrom","year":"1986","unstructured":"Engstrom FL, White HS, Kemp JW, Woodbury DM (1986) Acute and chronic acetazolamide administration in DBA and C57 mice: effects of age. Epilepsia 27(1):19\u201326","journal-title":"Epilepsia"},{"key":"3332_CR56","volume-title":"Wyllie's Treatment of Epilepsy","author":"M Barker-Haliski","year":"2015","unstructured":"Barker-Haliski M, White HS (2015) Antiepileptic drug development and experimental models. In: Wyllie E, Gidal BE, Goodkin HP (eds) Wyllie\u2019s Treatment of Epilepsy, 6th edn. Lippencott, Williams & Wilkins, Philadelphia","edition":"6"},{"key":"3332_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107750","author":"M Barker-Haliski","year":"2019","unstructured":"Barker-Haliski M, White HS (2019) Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening. Neuropharmacology. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107750","journal-title":"Neuropharmacology"},{"issue":"8","key":"3332_CR58","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1212\/WNL.0000000000003629","volume":"88","author":"AK Birnbaum","year":"2017","unstructured":"Birnbaum AK, Leppik IE, Svensden K, Eberly LE (2017) Prevalence of epilepsy\/seizures as a comorbidity of neurologic disorders in nursing homes. Neurology 88(8):750\u2013757. https:\/\/doi.org\/10.1212\/WNL.0000000000003629","journal-title":"Neurology"},{"issue":"10","key":"3332_CR59","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/phar.2012","volume":"37","author":"JM Conway","year":"2017","unstructured":"Conway JM, Eberly LE, Collins JF, Macias FM, Ramsay RE, Leppik IE, Birnbaum AK (2017) Factors in variability of serial gabapentin concentrations in elderly patients with epilepsy. Pharmacotherapy 37(10):1197\u20131203. https:\/\/doi.org\/10.1002\/phar.2012","journal-title":"Pharmacotherapy"},{"issue":"9","key":"3332_CR60","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1111\/epi.14519","volume":"59","author":"AR Polepally","year":"2018","unstructured":"Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK (2018) Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: effect of age. Epilepsia 59(9):1718\u20131726. https:\/\/doi.org\/10.1111\/epi.14519","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"3332_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","volume":"7","author":"HC Yang","year":"2010","unstructured":"Yang HC, Zuo Y, Fogo AB (2010) Models of chronic kidney disease. Drug Discov Today Dis Models 7(1\u20132):13\u201319. https:\/\/doi.org\/10.1016\/j.ddmod.2010.08.002","journal-title":"Drug Discov Today Dis Models"},{"key":"3332_CR62","doi-asserted-by":"publisher","first-page":"104719","DOI":"10.1016\/j.nbd.2019.104719","volume":"136","author":"M Beckman","year":"2020","unstructured":"Beckman M, Knox K, Koneval Z, Smith C, Jayadev S, Barker-Haliski M (2020) Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition. Neurobiol Dis 136:104719. https:\/\/doi.org\/10.1016\/j.nbd.2019.104719","journal-title":"Neurobiol Dis"},{"key":"3332_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14519","author":"AR Polepally","year":"2018","unstructured":"Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK (2018) Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: effect of age. Epilepsia. https:\/\/doi.org\/10.1111\/epi.14519","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"3332_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0920-1211(02)00068-2","volume":"50","author":"H Klitgaard","year":"2002","unstructured":"Klitgaard H, Matagne A, Lamberty Y (2002) Use of epileptic animals for adverse effect testing. Epilepsy Res 50(1\u20132):55\u201365","journal-title":"Epilepsy Res"},{"issue":"11","key":"3332_CR65","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1111\/j.1528-1167.2012.03541.x","volume":"53","author":"M Simonato","year":"2012","unstructured":"Simonato M, Loscher W, Cole AJ, Dudek FE, Engel J Jr, Kaminski RM, Loeb JA, Scharfman H, Staley KJ, Velisek L, Klitgaard H (2012) Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 53(11):1860\u20131867. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03541.x","journal-title":"Epilepsia"},{"issue":"11","key":"3332_CR66","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","volume":"29","author":"R Minkeviciene","year":"2009","unstructured":"Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H (2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29(11):3453\u20133462. https:\/\/doi.org\/10.1523\/JNEUROSCI.5215-08.2009","journal-title":"J Neurosci"},{"issue":"5","key":"3332_CR67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","volume":"55","author":"JJ Palop","year":"2007","unstructured":"Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer\u2019s disease. Neuron 55(5):697\u2013711. https:\/\/doi.org\/10.1016\/j.neuron.2007.07.025","journal-title":"Neuron"},{"issue":"1\u20132","key":"3332_CR68","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eplepsyres.2011.01.003","volume":"94","author":"S Ziyatdinova","year":"2011","unstructured":"Ziyatdinova S, Gurevicius K, Kutchiashvili N, Bolkvadze T, Nissinen J, Tanila H, Pitkanen A (2011) Spontaneous epileptiform discharges in a mouse model of Alzheimer\u2019s disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res 94(1\u20132):75\u201385. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.01.003","journal-title":"Epilepsy Res"},{"issue":"1","key":"3332_CR69","doi-asserted-by":"publisher","first-page":"a006304","DOI":"10.1101\/cshperspect.a006304","volume":"2","author":"B De Strooper","year":"2012","unstructured":"De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2(1):a006304. https:\/\/doi.org\/10.1101\/cshperspect.a006304","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"3332_CR70","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1084\/jem.20081588","volume":"205","author":"H Qing","year":"2008","unstructured":"Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W, Wang K, Song W (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models. J Exp Med 205(12):2781\u20132789. https:\/\/doi.org\/10.1084\/jem.20081588","journal-title":"J Exp Med"},{"issue":"6","key":"3332_CR71","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.yebeh.2004.08.021","volume":"5","author":"M Bialer","year":"2004","unstructured":"Bialer M, Twyman RE, White HS (2004) Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 5(6):866\u2013872","journal-title":"Epilepsy Behav"},{"key":"3332_CR72","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3389\/fneur.2019.01151","volume":"10","author":"I Gureviciene","year":"2019","unstructured":"Gureviciene I, Ishchenko I, Ziyatdinova S, Jin N, Lipponen A, Gurevicius K, Tanila H (2019) Characterization of epileptic spiking associated with brain amyloidosis in APP\/PS1 mice. Front Neurol 10:1151. https:\/\/doi.org\/10.3389\/fneur.2019.01151","journal-title":"Front Neurol"},{"issue":"1","key":"3332_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-015-0110-9","volume":"7","author":"HB Nygaard","year":"2015","unstructured":"Nygaard HB, Kaufman AC, Sekine-Konno T, Huh LL, Going H, Feldman SJ, Kostylev MA, Strittmatter SM (2015) Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer\u2019s disease mouse model. Alzheimers Res Ther 7(1):25. https:\/\/doi.org\/10.1186\/s13195-015-0110-9","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"3332_CR74","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/cns.12144","volume":"19","author":"JQ Shi","year":"2013","unstructured":"Shi JQ, Wang BR, Tian YY, Xu J, Gao L, Zhao SL, Jiang T, Xie HG, Zhang YD (2013) Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe\/PS1dE9 transgenic mice. CNS Neurosci Ther 19(11):871\u2013881. https:\/\/doi.org\/10.1111\/cns.12144","journal-title":"CNS Neurosci Ther"},{"key":"3332_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2015.02.005","volume":"112","author":"S Ziyatdinova","year":"2015","unstructured":"Ziyatdinova S, Viswanathan J, Hiltunen M, Tanila H, Pitkanen A (2015) Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer\u2019s disease is not long-lasting after treatment discontinuation. Epilepsy Res 112:43\u201355. https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.02.005","journal-title":"Epilepsy Res"},{"issue":"3","key":"3332_CR76","first-page":"741","volume":"232","author":"SG Piredda","year":"1985","unstructured":"Piredda SG, Woodhead JH, Swinyard EA (1985) Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmacol Exp Ther 232(3):741\u2013745","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3332_CR77","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/epi.13340","volume":"57","author":"H Klitgaard","year":"2016","unstructured":"Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B (2016) Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 57(4):538\u2013548. https:\/\/doi.org\/10.1111\/epi.13340","journal-title":"Epilepsia"},{"issue":"2","key":"3332_CR78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/epi.13267","volume":"57","author":"JM Nicolas","year":"2016","unstructured":"Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2):201\u2013209. https:\/\/doi.org\/10.1111\/epi.13267","journal-title":"Epilepsia"},{"issue":"1\u20133","key":"3332_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2009.03.025","volume":"610","author":"W Loscher","year":"2009","unstructured":"Loscher W (2009) Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 610(1\u20133):1\u201311. https:\/\/doi.org\/10.1016\/j.ejphar.2009.03.025","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3332_CR80","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1038\/s41598-020-68845-y","volume":"10","author":"N Jin","year":"2020","unstructured":"Jin N, Ziyatdinova S, Gureviciene I, Tanila H (2020) Response of spike-wave discharges in aged APP\/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs. Sci Rep 10(1):11851. https:\/\/doi.org\/10.1038\/s41598-020-68845-y","journal-title":"Sci Rep"},{"key":"3332_CR81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","volume":"126","author":"W Loscher","year":"2016","unstructured":"Loscher W (2016) Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res 126:157\u2013184. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.05.016","journal-title":"Epilepsy Res"},{"issue":"1\u20132","key":"3332_CR82","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF02229083","volume":"16","author":"C Marescaux","year":"1995","unstructured":"Marescaux C, Vergnes M (1995) Genetic Absence Epilepsy in Rats from Strasbourg (GAERS). Ital J Neurol Sci 16(1\u20132):113\u2013118","journal-title":"Ital J Neurol Sci"},{"key":"3332_CR83","doi-asserted-by":"publisher","first-page":"108661","DOI":"10.1016\/j.biopha.2019.108661","volume":"113","author":"PR Manzine","year":"2019","unstructured":"Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, Di Luca M, Endres K, Olloquequi J, Camins A, Cominetti MR (2019) ADAM10 in Alzheimer\u2019s disease: pharmacological modulation by natural compounds and its role as a peripheral marker. Biomed Pharmacother 113:108661. https:\/\/doi.org\/10.1016\/j.biopha.2019.108661","journal-title":"Biomed Pharmacother"},{"issue":"32","key":"3332_CR84","doi-asserted-by":"publisher","first-page":"12915","DOI":"10.1523\/JNEUROSCI.5910-12.2013","volume":"33","author":"J Prox","year":"2013","unstructured":"Prox J, Bernreuther C, Altmeppen H, Grendel J, Glatzel M, D\u2019Hooge R, Stroobants S, Ahmed T, Balschun D, Willem M, Lammich S, Isbrandt D, Schweizer M, Horre K, De Strooper B, Saftig P (2013) Postnatal disruption of the disintegrin\/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions. J Neurosci 33(32):12915\u201312928. https:\/\/doi.org\/10.1523\/JNEUROSCI.5910-12.2013","journal-title":"J Neurosci"},{"issue":"7","key":"3332_CR85","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1111\/jcmm.14307","volume":"23","author":"X Zhou","year":"2019","unstructured":"Zhou X, Tao H, Cai Y, Cui L, Zhao B, Li K (2019) Stage-dependent involvement of ADAM10 and its significance in epileptic seizures. J Cell Mol Med 23(7):4494\u20134504. https:\/\/doi.org\/10.1111\/jcmm.14307","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3332_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12974-018-1260-z","volume":"15","author":"X Zhu","year":"2018","unstructured":"Zhu X, Li X, Zhu M, Xu K, Yang L, Han B, Huang R, Zhang A, Yao H (2018) Metalloprotease Adam10 suppresses epilepsy through repression of hippocampal neuroinflammation. J Neuroinflammation 15(1):221. https:\/\/doi.org\/10.1186\/s12974-018-1260-z","journal-title":"J Neuroinflammation"},{"issue":"4","key":"3332_CR87","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer\u2019s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32(4):486\u2013510. https:\/\/doi.org\/10.1007\/s00259-005-1762-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3332_CR88","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1196\/annals.1427.007","volume":"1147","author":"L Mosconi","year":"2008","unstructured":"Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer\u2019s disease. Ann N Y Acad Sci 1147:180\u2013195. https:\/\/doi.org\/10.1196\/annals.1427.007","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"3332_CR89","doi-asserted-by":"publisher","first-page":"e79977","DOI":"10.1371\/journal.pone.0079977","volume":"8","author":"F Ding","year":"2013","unstructured":"Ding F, Yao J, Rettberg JR, Chen S, Brinton RD (2013) Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer\u2019s mouse brain: implication for bioenergetic intervention. PLoS ONE 8(11):e79977. https:\/\/doi.org\/10.1371\/journal.pone.0079977","journal-title":"PLoS ONE"},{"issue":"12","key":"3332_CR90","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.ebiom.2015.11.002","volume":"2","author":"LP Klosinski","year":"2015","unstructured":"Klosinski LP, Yao J, Yin F, Fonteh AN, Harrington MG, Christensen TA, Trushina E, Brinton RD (2015) White matter lipids as a Ketogenic fuel supply in aging female brain: implications for Alzheimer\u2019s disease. EBioMedicine 2(12):1888\u20131904. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.002","journal-title":"EBioMedicine"},{"issue":"34","key":"3332_CR91","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1073\/pnas.0903563106","volume":"106","author":"J Yao","year":"2009","unstructured":"Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer\u2019s pathology in female mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 106(34):14670\u201314675. https:\/\/doi.org\/10.1073\/pnas.0903563106","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"3332_CR92","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1212\/WNL.56.6.820","volume":"56","author":"M de Leon","year":"2001","unstructured":"de Leon M, Bobinski M, Convit A, Wolf O, Insausti R (2001) Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 56(6):820\u2013821","journal-title":"Neurology"},{"key":"3332_CR93","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.expneurol.2015.06.012","volume":"271","author":"P Bhuyan","year":"2015","unstructured":"Bhuyan P, Patel DC, Wilcox KS, Patel M (2015) Oxidative stress in murine Theiler\u2019s virus-induced temporal lobe epilepsy. Exp Neurol 271:329\u2013334. https:\/\/doi.org\/10.1016\/j.expneurol.2015.06.012","journal-title":"Exp Neurol"},{"issue":"1","key":"3332_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02251132","volume":"3","author":"S Hoyer","year":"1991","unstructured":"Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3(1):1\u201314","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"3332_CR95","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fncel.2019.00172","volume":"13","author":"JM Rho","year":"2019","unstructured":"Rho JM, Shao LR, Stafstrom CE (2019) 2-deoxyglucose and beta-hydroxybutyrate: metabolic agents for seizure control. Front Cell Neurosci 13:172. https:\/\/doi.org\/10.3389\/fncel.2019.00172","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"3332_CR96","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ana.21603","volume":"65","author":"CE Stafstrom","year":"2009","unstructured":"Stafstrom CE, Ockuly JC, Murphree L, Valley MT, Roopra A, Sutula TP (2009) Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Ann Neurol 65(4):435\u2013447. https:\/\/doi.org\/10.1002\/ana.21603","journal-title":"Ann Neurol"},{"issue":"4","key":"3332_CR97","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-180656","volume":"66","author":"H Jiang","year":"2018","unstructured":"Jiang H, Jayadev S, Lardelli M, Newman M (2018) A review of the familial Alzheimer\u2019s disease locus PRESENILIN 2 and its relationship to PRESENILIN 1. J Alzheimers Dis 66(4):1323\u20131339. https:\/\/doi.org\/10.3233\/JAD-180656","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"3332_CR98","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1471-4159.2005.03266.x","volume":"94","author":"JC Wiley","year":"2005","unstructured":"Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M (2005) Familial Alzheimer\u2019s disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem 94(5):1189\u20131201. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03266.x","journal-title":"J Neurochem"},{"issue":"Pt 4","key":"3332_CR99","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/brain\/awq033","volume":"133","author":"S Jayadev","year":"2010","unstructured":"Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD (2010) Alzheimer\u2019s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133(Pt 4):1143\u20131154. https:\/\/doi.org\/10.1093\/brain\/awq033","journal-title":"Brain"},{"issue":"10","key":"3332_CR100","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1212\/wnl.54.10.2006","volume":"54","author":"U Finckh","year":"2000","unstructured":"Finckh U, Alberici A, Antoniazzi M, Benussi L, Fedi V, Giannini C, Gal A, Nitsch RM, Binetti G (2000) Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 54(10):2006\u20132008. https:\/\/doi.org\/10.1212\/wnl.54.10.2006","journal-title":"Neurology"},{"key":"3332_CR101","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.neurobiolaging.2015.09.016","volume":"37","author":"C Blauwendraat","year":"2016","unstructured":"Blauwendraat C, Wilke C, Jansen IE, Schulte C, Simon-Sanchez J, Metzger FG, Bender B, Gasser T, Maetzler W, Rizzu P, Heutink P, Synofzik M (2016) Pilot whole-exome sequencing of a German early-onset Alzheimer\u2019s disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiol Aging 37:208. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.09.016","journal-title":"Neurobiol Aging"},{"key":"3332_CR102","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.brainresbull.2013.06.002","volume":"97","author":"L Yan","year":"2013","unstructured":"Yan L, Li L, Han W, Pan B, Xue X, Mei B (2013) Age-related neuropsychiatric symptoms in presenilins conditional double knockout mice. Brain Res Bull 97:104\u2013111. https:\/\/doi.org\/10.1016\/j.brainresbull.2013.06.002","journal-title":"Brain Res Bull"},{"issue":"5","key":"3332_CR103","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jnc.12400","volume":"127","author":"S Jayadev","year":"2013","unstructured":"Jayadev S, Case A, Alajajian B, Eastman AJ, Moller T, Garden GA (2013) Presenilin 2 influences miR146 level and activity in microglia. J Neurochem 127(5):592\u2013599. https:\/\/doi.org\/10.1111\/jnc.12400","journal-title":"J Neurochem"},{"issue":"12","key":"3332_CR104","doi-asserted-by":"publisher","first-page":"e15743","DOI":"10.1371\/journal.pone.0015743","volume":"5","author":"S Jayadev","year":"2010","unstructured":"Jayadev S, Case A, Eastman AJ, Nguyen H, Pollak J, Wiley JC, Moller T, Morrison RS, Garden GA (2010) Presenilin 2 is the predominant gamma-secretase in microglia and modulates cytokine release. PLoS ONE 5(12):e15743. https:\/\/doi.org\/10.1371\/journal.pone.0015743","journal-title":"PLoS ONE"},{"issue":"2","key":"3332_CR105","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3233\/JAD-200492","volume":"77","author":"S Fung","year":"2020","unstructured":"Fung S, Smith CL, Prater KE, Case A, Green K, Osnis L, Winston C, Kinoshita Y, Sopher B, Morrison RS, Garden GA, Jayadev S (2020) Early-onset familial Alzheimer disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype. J Alzheimers Dis 77(2):675\u2013688. https:\/\/doi.org\/10.3233\/JAD-200492","journal-title":"J Alzheimers Dis"},{"key":"3332_CR106","doi-asserted-by":"crossref","unstructured":"Barker-Haliski ML, Heck TD, Dahle EJ, Vanegas F, Pruess TH, Wilcox KS, White HS (2016) Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the theiler\u2019s virus model of temporal lobe epilepsy. Epilepsia (in press)","DOI":"10.1111\/epi.13577"},{"key":"3332_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1481-5","author":"A Vezzani","year":"2015","unstructured":"Vezzani A, Fujinami RS, White HS, Preux PM, Blumcke I, Sander JW, Loscher W (2015) Infections, inflammation and epilepsy. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-015-1481-5","journal-title":"Acta Neuropathol"},{"issue":"4","key":"3332_CR108","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/archneurol.2009.15","volume":"66","author":"JJ Palop","year":"2009","unstructured":"Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66(4):435\u2013440. https:\/\/doi.org\/10.1001\/archneurol.2009.15","journal-title":"Arch Neurol"},{"issue":"4","key":"3332_CR109","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/acel.12480","volume":"15","author":"VN Gladyshev","year":"2016","unstructured":"Gladyshev VN (2016) Aging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes. Aging Cell 15(4):594\u2013602. https:\/\/doi.org\/10.1111\/acel.12480","journal-title":"Aging Cell"},{"issue":"2\u20133","key":"3332_CR110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00429-009-0227-3","volume":"214","author":"GA Elder","year":"2010","unstructured":"Elder GA, Gama Sosa MA, De Gasperi R, Dickstein DL, Hof PR (2010) Presenilin transgenic mice as models of Alzheimer\u2019s disease. Brain Struct Funct 214(2\u20133):127\u2013143. https:\/\/doi.org\/10.1007\/s00429-009-0227-3","journal-title":"Brain Struct Funct"},{"issue":"21","key":"3332_CR111","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1073\/pnas.96.21.11872","volume":"96","author":"A Herreman","year":"1999","unstructured":"Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 96(21):11872\u201311877","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3332_CR112","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1124\/jpet.104.071027","volume":"311","author":"R Minkeviciene","year":"2004","unstructured":"Minkeviciene R, Banerjee P, Tanila H (2004) Memantine improves spatial learning in a transgenic mouse model of Alzheimer\u2019s disease. J Pharmacol Exp Ther 311(2):677\u2013682. https:\/\/doi.org\/10.1124\/jpet.104.071027","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3332_CR113","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.nbd.2006.04.013","volume":"23","author":"M Oksman","year":"2006","unstructured":"Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP\/PS1 transgenic mice. Neurobiol Dis 23(3):563\u2013572. https:\/\/doi.org\/10.1016\/j.nbd.2006.04.013","journal-title":"Neurobiol Dis"},{"issue":"46","key":"3332_CR114","doi-asserted-by":"publisher","first-page":"32535","DOI":"10.1074\/jbc.274.46.32535","volume":"274","author":"MA Leissring","year":"1999","unstructured":"Leissring MA, Parker I, LaFerla FM (1999) Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem 274(46):32535\u201332538","journal-title":"J Biol Chem"},{"issue":"7","key":"3332_CR115","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1073\/pnas.1100735108","volume":"108","author":"E Zampese","year":"2011","unstructured":"Zampese E, Fasolato C, Kipanyula MJ, Bortolozzi M, Pozzan T, Pizzo P (2011) Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci USA 108(7):2777\u20132782. https:\/\/doi.org\/10.1073\/pnas.1100735108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"3332_CR116","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.celrep.2016.05.013","volume":"15","author":"R Filadi","year":"2016","unstructured":"Filadi R, Greotti E, Turacchio G, Luini A, Pozzan T, Pizzo P (2016) Presenilin 2 modulates endoplasmic reticulum-mitochondria coupling by tuning the antagonistic effect of mitofusin 2. Cell Rep 15(10):2226\u20132238. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.013","journal-title":"Cell Rep"},{"issue":"5","key":"3332_CR117","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ceca.2016.06.008","volume":"60","author":"M Agostini","year":"2016","unstructured":"Agostini M, Fasolato C (2016) When, where and how? Focus on neuronal calcium dysfunctions in Alzheimer\u2019s Disease. Cell Calcium 60(5):289\u2013298. https:\/\/doi.org\/10.1016\/j.ceca.2016.06.008","journal-title":"Cell Calcium"},{"issue":"12","key":"3332_CR118","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/nn.4163","volume":"18","author":"MA Busche","year":"2015","unstructured":"Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Forstl H, Konnerth A (2015) Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer\u2019s models. Nat Neurosci 18(12):1725\u20131727. https:\/\/doi.org\/10.1038\/nn.4163","journal-title":"Nat Neurosci"},{"issue":"1","key":"3332_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2014.08.014","volume":"36","author":"A Stargardt","year":"2015","unstructured":"Stargardt A, Swaab DF, Bossers K (2015) Storm before the quiet: neuronal hyperactivity and Abeta in the presymptomatic stages of Alzheimer\u2019s disease. Neurobiol Aging 36(1):1\u201311. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.08.014","journal-title":"Neurobiol Aging"},{"key":"3332_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12250","author":"M Dibue","year":"2013","unstructured":"Dibue M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, Schneider T (2013) Ca 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo. Epilepsia. https:\/\/doi.org\/10.1111\/epi.12250","journal-title":"Epilepsia"},{"issue":"9","key":"3332_CR121","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.neurobiolaging.2009.09.002","volume":"32","author":"DL Vogt","year":"2011","unstructured":"Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW (2011) Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 32(9):1725\u20131729. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.09.002","journal-title":"Neurobiol Aging"},{"issue":"9","key":"3332_CR122","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/WNL.0000000000003048","volume":"87","author":"A Zarea","year":"2016","unstructured":"Zarea A, Charbonnier C, Rovelet-Lecrux A, Nicolas G, Rousseau S, Borden A, Pariente J, Le Ber I, Pasquier F, Formaglio M, Martinaud O, Rollin-Sillaire A, Sarazin M, Croisile B, Boutoleau-Bretonniere C, Ceccaldi M, Gabelle A, Chamard L, Blanc F, Sellal F, Paquet C, Campion D, Hannequin D, Wallon D, Collaborators PG (2016) Seizures in dominantly inherited Alzheimer disease. Neurology 87(9):912\u2013919. https:\/\/doi.org\/10.1212\/WNL.0000000000003048","journal-title":"Neurology"},{"issue":"6","key":"3332_CR123","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s11064-018-2544-5","volume":"43","author":"L Wu","year":"2018","unstructured":"Wu L, Li Y, Yu M, Yang F, Tu M, Xu H (2018) Notch signaling regulates microglial activation and inflammatory reactions in a rat model of temporal lobe epilepsy. Neurochem Res 43(6):1269\u20131282. https:\/\/doi.org\/10.1007\/s11064-018-2544-5","journal-title":"Neurochem Res"},{"key":"3332_CR124","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mehy.2016.12.006","volume":"99","author":"U Damar","year":"2017","unstructured":"Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A (2017) Huperzine A: a promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer\u2019s disease. Med Hypotheses 99:57\u201362. https:\/\/doi.org\/10.1016\/j.mehy.2016.12.006","journal-title":"Med Hypotheses"},{"issue":"6","key":"3332_CR125","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00210-017-1357-4","volume":"390","author":"ME Sorial","year":"2017","unstructured":"Sorial ME, El Sayed NSED (2017) Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer\u2019s disease mouse model: possible involvement of the cholinergic system. Naunyn Schmiedebergs Arch Pharmacol 390(6):581\u2013593","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"3332_CR126","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.3390\/ijms20123003","volume":"20","author":"BA Owona","year":"2019","unstructured":"Owona BA, Zug C, Schluesener HJ, Zhang Z-Y (2019) Amelioration of behavioral impairments and neuropathology by antiepileptic drug topiramate in a transgenic Alzheimer\u2019s disease model mice, APP\/PS1. Int J Mol Sci 20(12):3003","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3332_CR127","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/abbs\/gmw085","volume":"48","author":"Z Long","year":"2016","unstructured":"Long Z, Zeng Q, Wang K, Sharma A, He G (2016) Gender difference in valproic acid-induced neuroprotective effects on APP\/PS1 double transgenic mice modeling Alzheimer\u2019s disease. Acta Biochim Biophys Sin 48(10):930\u2013938","journal-title":"Acta Biochim Biophys Sin"},{"key":"3332_CR128","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neurobiolaging.2020.08.013","volume":"96","author":"JL Klee","year":"2020","unstructured":"Klee JL, Kiliaan AJ, Lipponen A, Battaglia FP (2020) Reduced firing rates of pyramidal cells in the frontal cortex of APP\/PS1 can be restored by acute treatment with levetiracetam. Neurobiol Aging 96:79\u201386","journal-title":"Neurobiol Aging"},{"key":"3332_CR129","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nlm.2013.02.001","volume":"102","author":"L Devi","year":"2013","unstructured":"Devi L, Ohno M (2013) Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer\u2019s disease in mice. Neurobiol Learn Mem 102:7\u201311","journal-title":"Neurobiol Learn Mem"},{"key":"3332_CR130","doi-asserted-by":"publisher","first-page":"801","DOI":"10.12659\/msm.898679","volume":"23","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang L, Wang R, Gao Y, Che H, Pan Y, Fu P (2017) Evaluating the effectiveness of GTM-1, rapamycin, and carbamazepine on autophagy and Alzheimer disease. Med Sci Monit 23:801\u2013808. https:\/\/doi.org\/10.12659\/msm.898679","journal-title":"Med Sci Monit"},{"issue":"1","key":"3332_CR131","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40478-017-0461-5","volume":"5","author":"T Umeda","year":"2017","unstructured":"Umeda T, Kimura T, Yoshida K, Takao K, Fujita Y, Matsuyama S, Sakai A, Yamashita M, Yamashita Y, Ohnishi K, Suzuki M, Takuma H, Miyakawa T, Takashima A, Morita T, Mori H, Tomiyama T (2017) Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer\u2019s disease: analysis of Osaka mutation-knockin mice. Acta Neuropathol Commun 5(1):59","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"3332_CR132","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s12640-014-9478-8","volume":"26","author":"C Quiroga","year":"2014","unstructured":"Quiroga C, Chaparro RE, Karlnoski R, Erasso D, Gordon M, Morgan D, Bosco G, Rubini A, Parmagnani A, Paoli A, Mangar D, Camporesi EM (2014) Effects of repetitive exposure to anesthetics and analgesics in the Tg2576 mouse Alzheimer\u2019s model. Neurotox Res 26(4):414\u2013421","journal-title":"Neurotox Res"},{"key":"3332_CR133","first-page":"1","volume":"2016","author":"K Wang","year":"2016","unstructured":"Wang K, Fernandez-Escobar A, Han S, Zhu P, Wang J-H, Sun Y (2016) Lamotrigine reduces inflammatory response and ameliorates executive function deterioration in an Alzheimer\u2019s-like mouse model. Biomed Res Int 2016:1\u20139","journal-title":"Biomed Res Int"},{"issue":"12","key":"3332_CR134","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1016\/j.neurobiolaging.2014.06.009","volume":"35","author":"M-Y Zhang","year":"2014","unstructured":"Zhang M-Y, Zheng C-Y, Zou M-M, Zhu J-W, Zhang Y, Wang J, Liu C-F, Li Q-F, Xiao Z-C, Li S, Ma Q-H, Xu R-X (2014) Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP\/PS1 transgenic mice. Neurobiol Aging 35(12):2713\u20132725","journal-title":"Neurobiol Aging"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-021-03332-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T19:17:39Z","timestamp":1724959059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-021-03332-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":134,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3332"],"URL":"https:\/\/doi.org\/10.1007\/s11064-021-03332-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}